propofol. We have subset the original dataset to the 2,210 patients who received one of those regimens and report a regression-based analysis as well as a propensity-matching analysis. Table 3 shows the comparison between regimens midazolam plus etomidate and midazolam plus propofol among the subset of patients who received one of the regimens using the suggested propensity-matching approach and a regression modeling approach. In neither case would we conclude any difference between the treatments.
Correspondence
Correspondence propofol. We have subset the original dataset to the 2,210 patients who received one of those regimens and report a regression-based analysis as well as a propensity-matching analysis. Table 3 shows the comparison between regimens midazolam plus etomidate and midazolam plus propofol among the subset of patients who received one of the regimens using the suggested propensity-matching approach and a regression modeling approach. In neither case would we conclude any difference between the treatments.
Finally, Sanders et al. suggested that we adjust for hypertension as a potential confounder for the observed angiotensin-converting enzyme inhibitor effect seen in figure 3 of the original article. We agree that if interest was in angiotensin-converting enzyme inhibitor effects, controlling for hypertension would certainly be warranted. That said, even though we were explicit about showing all modeling results, our interest in including covariates was to control for confounding of etomidate effects. We are aware that one could always improve modeling approaches; however, ours was a prespecified model that we thought would be adequate (not perfect) in its capacity to control for confounding of etomidate associations with outcomes.
deserve credit for their review of the subject and detailed analysis of factors culminating in the death of their patient. The transparency required to present such a case is of benefit to all anesthesiologists, who can apply the principles described to improve safety for patients undergoing regional anesthesia techniques.
However, we were concerned that one integral factor contributing to the poor outcome in this case was not discussed, and that is the total dose of local anesthetic (LA) administered. We believe that a relative overdose of LA was administered and subsequent systemic absorption was likely a factor in the toxicity observed.
Total doses of LA used include 30 ml of mepivacaine 1.5% without epinephrine (450 mg) plus 10 ml of bupivacaine 0.25% with epinephrine 1:200,000 (25 mg). The dose of mepivacaine exceeds the manufacturer's recommended maximum dose of 400 mg for an adult. 2 Of note, the manufacturer's product information inserts for mepivacaine and bupivacaine additionally caution that the dose should be reduced for elderly or debilitated patients.* † Further to this point, maximum adult doses for LAs cited in textbooks often assume a adult patient of 70 kg. 2 When treating a patient less than the assumed weight, 45 kg in this case, the dose must be reduced. Lastly, an elderly, American Society of Anesthesiologists physical status 4 patient is presumed to have impaired hepatic and renal function, as well as increased susceptibility to toxicity because of cardiovascular disease and reduced serum protein binding capacity. 3 All these factors conspire to put such a patient at risk of local anesthetic systemic toxicity from seemingly "normal" doses of LA.
When a regional technique is chosen, LA dosing must take into account patient factors predisposing to local anesthetic systemic toxicity, and doses of LA must be reduced accordingly.
Total Local Anesthetic Administered Is Integral to the Syndrome of Local Anesthetic Systemic Toxicity

To the Editor:
We read with interest the report of local anesthetic systemic toxicity in the recent issue of AneSTHeSIOLOgy. 1 The authors Correspondence In Reply: We thank Drs. Petrar and Montemurro for their letter regarding our case scenario 1 and for outlining the impact of local anesthetic dosing on this case. These considerations are all important and relevant; the subject of this case scenario may indeed have received a relative overdose of local anesthetic. Although local anesthetic dosing is certainly germane to a discussion of systemic toxicity itself, we do not feel the dosing is central to the purpose of this article. Accepting that the case was performed in the manner it was with the dosing and technique used, there is still much to learn from this case. Because diagnostic error is now recognized as a critical problem of huge clinical and financial consequence by safety experts and both the Joint Commission and the American Medical Association, occurring with unacceptable frequency across all medical specialties, 2 we chose to focus on the cognitive factors that impacted the clinical decision making. These lessons are broadly applicable to all decision-making situations, well beyond the reach of this particular clinical situation.
We also thank Drs. Barrington and Weinberg for their comments on the possibility that fixation error occurred, and the importance of crisis resource management. The CRM can reduce the risk of LAST specifically and regional anesthesia in general.
